Hassounah Said A, Mesplède Thibault, Wainberg Mark A
McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada.
Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Pathog Immun. 2016 May 31;1(1):41-67. doi: 10.20411/pai.v1i1.104. eCollection 2016.
Since the discovery of the first inhibitors of HIV replication, drug resistance has been a major problem in HIV therapy due in part to the high mutation rate of HIV. Therefore, the development of a predictive animal model is important to identify impending resistance mutations and to possibly inform treatment decisions. Significant advances have been made possible through use of nonhuman primates infected by SIV, SHIV, and simian-tropic HIV-1 (stHIV-1), and use of humanized mouse models of HIV-1 infections. In this review, we describe some of the findings from animal models used for the preclinical testing of integrase strand transfer inhibitors. These models have led to important findings about the potential role of integrase strand transfer inhibitors in both the prevention and treatment of HIV-1 infection.
自从发现首批HIV复制抑制剂以来，耐药性一直是HIV治疗中的一个主要问题，部分原因是HIV的高突变率。因此，开发一种预测性动物模型对于识别即将出现的耐药性突变并可能为治疗决策提供依据非常重要。通过使用感染了SIV、SHIV和猿嗜性HIV-1（stHIV-1）的非人灵长类动物，以及使用HIV-1感染的人源化小鼠模型，已经取得了重大进展。在这篇综述中，我们描述了用于整合酶链转移抑制剂临床前测试的动物模型的一些研究结果。这些模型已经得出了关于整合酶链转移抑制剂在HIV-1感染的预防和治疗中的潜在作用的重要发现。
